International Clinical Trial: An exploratory study of adebelimab combined with chemotherapy with or without cetuximab as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133554) titled 'An exploratory study of adebelimab combined with chemotherapy with or without cetuximab as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma' on Sept. 29.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital of Dalian Medical University

Condition: Locally Advanced Head and Neck Squamous Cell Carcinoma

Intervention: Cohort 1: Adebrelimab + Chemotherapy + Cetuximab:Adebrelimab: Fixed dose of 1200 mg, IV infusion, Day 1. Infusion time should be controlled between 30 to 60 min, with a maximum of 2 hours. Chemotherapy: Albumin-bound...